Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568358 | 0.90 | GAA (0.42) | CYP17A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4568054 | 0.88 | SMN1; SMN2 (0.47) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL4568359 | 0.86 | RAB9A (0.39) | CYP17A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4568361 | 0.86 | TAS1R3 (0.41) | CYP17A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4568068 | 0.85 | TAS1R3 (0.50) | CYP17A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4568360 | 0.85 | MAPT (0.36) | ANO1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4568012 | 0.85 | KMT2A (0.45) | ANO1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4568049 | 0.85 | RAB9A (0.46) | ANO1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4568067 | 0.84 | KMT2A (0.50) | ANO1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4568052 | 0.84 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | CYP17A1 1315/4885ANO1 1346/4885NPC1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.